CDKN2A/B Homozygous Deletion Sensitizes IDH-Mutant Glioma to CDK4/6 Inhibition.

Ali M Nasser Lisa Melamed Ethan A Wetzel Jenny Chia-Chen Chang Hiroaki Nagashima Yosuke Kitagawa Logan Muzyka Hiroaki Wakimoto Daniel P Cahill Julie J Miller

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

IDH-mutant gliomas with deletion of CDKN2A/B are sensitized to CDK4/6 inhibitors. These results support the investigation of the use of these agents in a clinical setting.

Keyphrases

wild type
cell cycle
low grade
high grade
induced apoptosis
cell proliferation